MAPK3 and Alzheimer disease: Western blotting assay showed ox-LDL increased the expression of p-ERK1/2 in VSMCs (p < 0.05, Figure 3), and the treatment with AD and U0126 significantly suppressed p-ERK1/2 expression at 12, 24, and 48 h (p < 0.05 for AD and p < 0.01 for U0126, Figure 3).